Hepato-preventive and anti-apoptotic role of boric acid against liver injury induced by cyclophosphamide

Cengiz, Mustafa; Yıldız, Songül Çetik; Demir, Cemil; Şahin, İlknur Kulcanay; Teksoy, Ozgun; Ayhancı, Adnan

doi:10.1016/j.jtemb.2019.01.013

Cited by 31 publications

(24 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Decrease in ALB level is related to impairment in hepatic protein synthesis capacity and transport. These observed distortions strongly suggest hepatocellular damage due to CYP toxicity in consistent with published papers 7 14 15 . Cyclophosphamide is known to promote reactive oxygen species (ROS) generation that are capable of inducing tissue deterioration not only in the liver but also in the kidney, heart, testis and brain 22 .…”

Section: Discussionsupporting

confidence: 90%

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Exhibits Antioxidant Mechanism for Abrogation of Cyclophosphamide-Induced Cardiac Damage and Oxidative Hepatorenal Toxicity in Rats

et al. 2022

View full text Add to dashboard Cite

Cyclophosphamide (CYP) is a potent DNA-interactive anticancer drug; however, its clinical drawbacks are chiefly associated with induction of oxidative multi-organ toxicity. Sitagliptin (STG) is an antidiabetic dipeptidyl peptidase-4 inhibitor drug with antioxidant efficacy. Herein, we have explored whether STG could abrogate the CYP-induced oxidative stress-mediated cardiac and hepatorenal toxicities in male rats. Sitagliptin (20 mg/kg, o.p) was administered to rats for 5 consecutive days against organ toxicities induced by CYP (200 mg/kg, i.p) on day 5 only. CYP induced marked injuries in the liver, kidney and heart underscored by prominent increases in serum activities of ALT, AST, LDH, creatine kinase and levels of urea, uric acid and creatinine, while albumin level significantly decreased compared to normal control rats. Further, CYP considerably reduced the activities of SOD, CAT, GPx, and levels of GSH, whereas MDA level increased significantly in comparison to control rats. These biochemical alterations were confirmed by multiple histopathological lesions in the tissues. Interestingly, the STG pretreatment abrogated the biochemical and histopathological changes induced by CYP. These results provide first evidence that repurposing STG may protect the liver, kidney and heart from the oxidative deterioration associated with CYP chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 90%

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Exhibits Antioxidant Mechanism for Abrogation of Cyclophosphamide-Induced Cardiac Damage and Oxidative Hepatorenal Toxicity in Rats

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…The high incidence in both the studies of transaminases elevation (20% and 7.1%) is probably due to the hepatotoxic effect of Cyclophosphamide, used in more massive dosages than conventional chemotherapy. 21 Conclusions. Our experience gives evidence that lowdose pre-phase chemotherapy could be a safe and effective way to prevent adverse events not only in G-DLBCL, as Cui et al highlighted, but also in systemic DLBCL with gastrointestinal involvement.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Cyclophosphamide Low-Dose Pre-Phase Chemotherapy in Diffuse Large B Cell Lymphoma With Gastrointestinal Involvement

Guarnera

Meconi

Secchi

et al. 2022

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Introduction Gastric Diffuse large B‐cell lymphoma (DLBCL) is the most common extra-nodal site of lymphoma’s involvement (30%-40% of all extranodal lymphomas and 55%-65% of all gastrointestinal lymphomas). However, gastric localizations are also sometimes found in systemic DLBCL. Gastric complications such as bleeding, perforation and stenosis under chemotherapy are well documented. Methods We retrospectively analyzed 15 patients with newly diagnosed DLBCL with gastrointestinal involvement. Endoscopies were performed in these patients before and after treatment. Treatment consisted in cyclophosphamide low-dose pre-phase chemotherapy before conventional-dose chemotherapy. Results Endoscopy at staging detected ulcers in 12 patients (80%). After low-dose pre-phase chemotherapy GI ulcers healed in 91.6% of cases (1 ulcer detected). After the whole treatment (Low-dose pre-phase + chemotherapy) 9 patients (60%) achieved complete response, 4 patients (26.6%) partial response, 2 (13,3%) patients presented disease progression. The most frequent adverse event was neutropenia (73.3%); the most frequent non hematological adverse event was transaminases elevation (20%). Conclusion Cyclophosphamide low-dose pre-phase chemotherapy resulted a safe and effective way to prevent adverse events in systemic DLBCL with gastrointestinal involvement.

show abstract

“…ALT and AST are one of the important indicators reflecting the normal function of liver tissue, and its elevated content is often an important marker of liver function damage [37]. TNF-α, IFN-β, IL-6, MCP-1 and IL-4 are important inflammatory or anti-inflammatory factors, which are also one of the indicators of liver tissue damage [38,39].…”

Section: Agingmentioning

confidence: 99%

Overexpression of miR-142-5p inhibits the progression of nonalcoholic steatohepatitis by targeting TSLP and inhibiting JAK-STAT signaling pathway

Zhou

Wang

Lei

et al. 2020

Aging

View full text Add to dashboard Cite

show abstract

Hepato-preventive and anti-apoptotic role of boric acid against liver injury induced by cyclophosphamide

Cited by 31 publications

References 21 publications

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Exhibits Antioxidant Mechanism for Abrogation of Cyclophosphamide-Induced Cardiac Damage and Oxidative Hepatorenal Toxicity in Rats

Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Exhibits Antioxidant Mechanism for Abrogation of Cyclophosphamide-Induced Cardiac Damage and Oxidative Hepatorenal Toxicity in Rats

Efficacy and Safety of Cyclophosphamide Low-Dose Pre-Phase Chemotherapy in Diffuse Large B Cell Lymphoma With Gastrointestinal Involvement

Overexpression of miR-142-5p inhibits the progression of nonalcoholic steatohepatitis by targeting TSLP and inhibiting JAK-STAT signaling pathway

Contact Info

Product

Resources

About